Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019 - 2020)

Kymera Therapeutics (KYMR) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $5.9 million as the latest value for Q2 2020.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $5.9 million in Q2 2020 year-over-year; TTM through Jun 2020 was $5.9 million, a N/A change, with the full-year FY2019 number at $5.9 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $5.9 million for Q2 2020 at Kymera Therapeutics, roughly flat from $5.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $38.7 million in Q3 2019 to a low of $5.9 million in Q4 2019.